Sort   by:  
 Page size 
UnknownLutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE.
Not available
S-EPMC10142322 | biostudies-literature
UnknownA prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera® in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH).
Not available
S-EPMC9773621 | biostudies-literature
UnknownPhase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung.
Not available
S-EPMC7333915 | biostudies-literature
ClinicalA study to assess the schemas of retreatment with Lutathera in patients with new progression of intestinal well-differentiated neuroendocrine tumor.
Primary objectives: To evaluate the efficacy of two additional cycles of Lutathera (one injection every two months), compared to active surveillance during 6 months in patients already retreated with two cycles. Primary endpoints: Disease Control Rate at 6 months from randomization (defined as Compl...
2541272 | ecrin-mdr-crc
ClinicalAssessment of Retreatment With Lutathera in Patients With New Progression of Intestinal Well-differenciated NET
In France, since the reimbursement of Lutathera, this treatment is allowed for retreatment if patients still fulfill the criteria of its indication and 4 news cycles could be proposed. However, clinical practices are heterogeneous regarding the number of new cycles and most teams perform only two ad...
2382758 | ecrin-mdr-crc
ClinicalItalian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs
This is a multicentre long-term non-interventional study of adult subjects diagnosed with unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive GEP-NETs who have been prescribed Lutathera in standard clinical practice.
2365307 | ecrin-mdr-crc
UnknownPeptide receptor radionuclide therapy implementation and results in a predominantly gastrointestinal neuroendocrine tumor population: A two-year experience in a nonuniversity setting.
Not available
S-EPMC8896579 | biostudies-literature
UnknownRadioligand Therapy in Cancer Management: A Global Perspective.
Not available
S-EPMC12607575 | biostudies-literature
ClinicalA Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
This was a multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with Lutathera plus best supportive care (30 mg Octreotide LAR) to treatment with high dose (60 mg) Octreotide LAR in participants with metastasized or locally advanced, in...
2123805 | ecrin-mdr-crc
UnknownRadiolabeled Somatostatin Analogs-A Continuously Evolving Class of Radiopharmaceuticals.
Not available
S-EPMC8909681 | biostudies-literature
Sort   by:  
 Page size